Induction of HLA-A2-restricted CTL responses by a tubular structure carrying human melanoma epitopes

Vaccine

Volumn 20, Issue 19-20, 2002, Pages 2463-2473

  Ghosh, Mrinal K ^a   Li, Cui Ling ^b   Fayolle, Catherine ^b   Dadaglio, Gilles ^b   Murphy, Aileen ^c   Lemonnier, François A ^b   Roy, Polly ^a,c   Leclerc, Claude ^b  

^a University of Alabama at Birmingham   (United States)

^b INSTITUT PASTEUR   (France)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

Chimeric BTV NS1 tubules; CTL responses; HHD mice; Melanoma

Indexed keywords

EPITOPE; GLYCOPROTEIN GP 100; HLA A2 ANTIGEN; MELAN A; MELANOMA ANTIGEN; MELANOMA VACCINE; MONOPHENOL MONOOXYGENASE; RECOMBINANT ANTIGEN; CANCER VACCINE; GAMMA INTERFERON; PRIMER DNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTATION; ANTIGEN SPECIFICITY; ARTICLE; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; FUSION GENE; GENE CONSTRUCT; IMMUNE RESPONSE; IMMUNOMODULATION; IN VIVO STUDY; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN INDUCTION; RECOMBINANT GENE; TRANSGENIC MOUSE; AMINO ACID SEQUENCE; ANIMAL; BACULOVIRUS; BIOSYNTHESIS; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETICS; HUMAN; IMMUNOLOGY; MOUSE MUTANT; NUCLEOTIDE SEQUENCE; WESTERN BLOTTING;

AMINO ACID SEQUENCE; ANIMAL; BACULOVIRIDAE; BASE SEQUENCE; BLOTTING, WESTERN; CANCER VACCINES; DNA PRIMERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES; HLA-A2 ANTIGEN; HUMAN; INTERFERON TYPE II; MELANOMA; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; SUPPORT, NON-U.S. GOV'T; T-LYMPHOCYTES, CYTOTOXIC; ANIMALS; HUMANS;

EID: 0037035857     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(02)00185-8     Document Type: Article

References (41)

1. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression
2. Human tumor antigens recognized by T cells
3. Recognition of human melanoma cells by HLA-A2.1-restricted cytotoxic T lymphocytes is mediated by at least six shared peptide epitopes
4. Genes coding for tumor antigens recognized by cytolytic T lymphocytes
5. Cancer vaccines based on the identification of genes encoding cancer regression antigens
6. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma
7. Peptide vaccination can lead to enhanced tumor growth through specific T-cell tolerance induction
8. Chimeric papillomavirus virus-like particles induce a murine self-antigen-specific protective and therapeutic antitumor immune response
9. Induction of potent antitumor CTL responses by recombinant vaccinia encoding a Melan-A peptide analogue
10. Active immunotherapy of cancer with a nonreplicating recombinant fowlpox virus encoding a model tumor-associated antigen
11. Antigen-specific tumor vaccines: Development and characterization of recombinant adenoviruses encoding Mart-1 or gp100 for cancer therapy
12. Immunization of HLA-A2+ melanoma patients with MAGE-3 or Melan-A peptide-pulsed autologous peripheral blood mononuclear cells plus recombinant human interleukin 12
13. Dendritic cells infected with a vaccinia vector carrying the human gp100 gene simultaneously present multiple specificities and elicit high-affinity T cells ractive to multiple epitopes and restricted by HLA-A2 and -A3
14. Vaccination of melanoma patients with peptide or tumor-lysate pulsed dendritic cells
15. Induction of protective antiviral cytotoxic T cells by a tubular structure capable of carrying large foreign sequences
16. HLA-A2.1-restricted education and cytolytic activity of CD8(+) T lymphocytes from β2 microglobulin (β2m) HLA-A2-1 monochain transgenic H2Db β2m double knockout mice
17. H-2 class I knockout, HLA-A2.1-transgenic mice: Evaluation of antitumor immunotherapeutic strategies
18. An HLA-A2 restricted Tyrosinase antigen on melanoma cells results from posttranslational modification and suggests a novel pathway for processing of membrane proteins
19. Two Tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytotoxic T lymphocytes
20. A peptide recognized by human cytolytic T lymphocytes on HLA-A2 melanoma is encoded by an intron sequence of the N-acetylglucosaminyltransferase V gene
21. Analogues of CTL epitopes with improved MHC class I binding capacity elicit anti-melanoma CTL recognizing the wild type epitope
22. Identification of the immunodominant peptides of the Mart-1 human melanoma antigen recognized by the majority of HLA-A2 restricted tumor infiltrating lymphocytes
23. A plaque assay for nuclear polyhedrosis viruses using a solid overlay
24. Characterization and modification of the carboxy-terminal sequences of bluetongue virus type 10 NS1 protein in relation to tubule formation and location of an antigenic epitope in the vicinity of the carboxy terminus of the protein
25. DNA sequencing with chain-terminating inhibitors
26. Lipofection: A highly efficiency, lipid-mediated DNA-transfection procedure
27. A method for producing recombinant baculovirus expression vectors at high frequency
28. Mutation of either two cysteine residues or deletion of the amino or carboxy terminus of nonstructural protein NS1 of bluetongue virus abrogates virus-specified tubule formation in insect cells
29. Bluetongue virus tubules made in insect cells by recombinant baculoviruses: Expression of NS1 gene of bluetongue virus serotype 10
30. Differences and similarities in the A2.1-restricted cytotoxic T cells in humans and in human leukocyte antigen-transgenic mice
31. Cross-presentation, dendritic cells, tolerance and immunity
32. Efficient processing of an antigenic sequence for presentation by MHC class I molecules depends on its neighbouring residues in the protein
33. Differential effects of flanking residues on presentation of epitopes from chimeric peptides
34. + cytotoxic T cells: Implications for vaccine design
35. + cytotoxic T cell epitopes by DNA vaccination
36. Efficient major histocompatibility complex class I presentation of exogenous antigen upon phagocytosis by macrophages
37. Targeting antigen into the phagocytic pathway in vivo induces protective tumor immunity
38. Particulate naturally processed peptides prime a cytotoxic response against human melanoma in vitro
39. In vivo induction of high avidity and high frequency of CTL is associated with anti-viral protective immunity
40. Recombinant parvovirus-like particles as an antigen carrier: A novel nonreplicative exogenous antigen to elicit protective antiviral cytotoxic T cells